MedPath

Lysergic acid diethylamide

Generic Name
Lysergic acid diethylamide
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H25N3O
CAS Number
50-37-3
Unique Ingredient Identifier
8NA5SWF92O
Background

Debate continues over the nature and causes of chronic flashbacks. Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder. Many emotionally intense experiences can lead to flashbacks when a person is reminded acutely of the original experience. However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

Associated Conditions
-
Associated Therapies
-

MindMed to lead first LSD Phase 3 trials for anxiety

MindMed plans pivotal LSD study for generalized anxiety disorder, aiming to innovate stagnant anxiety treatment landscape with MM-120, a pharmacologically optimized form of LSD, which showed promising Phase 2b results. The company envisions a treatment model similar to Spravato but with potentially fewer restrictions, targeting a growing network of interventional psychiatry clinics.
psypost.org
·

Psychedelic drug DOI activates specific brain neurons to ease anxiety

New study in *Neuron* reveals DOI, a psychedelic drug, reduces anxiety by activating ventral hippocampus neurons in mice and rats, offering insights into potential future anxiety treatments.

Expert recommendations for Germany's integration of psychedelic-assisted therapy

Psychedelic-assisted therapy (PAT) merges psychotherapy with psychedelic states, facilitated by substances like LSD, psilocybin, and MDMA, showing potential in treating PTSD, TRD, MDD, and other conditions. Despite being classified as Schedule I drugs, their therapeutic potential is increasingly recognized, leading to FDA Breakthrough Therapy designations for MDMA and psilocybin. Recent research suggests these substances reopen a 'critical period' in the brain, enhancing social reward learning and brain plasticity. Methodologically rigorous clinical research indicates substantial long-term symptom alleviation, with single sessions leading to significant symptom reduction and remission lasting up to twelve months. Despite regulatory challenges, ongoing research and clinical trials continue to explore and validate the therapeutic benefits of PAT.
theatlantic.com
·

When Does a High Become a Trip?

Ibogaine induces intense hallucinations, while tabernanthalog, a non-hallucinogenic analogue, offers altered states without trips. The definition of a trip is evolving as researchers develop non-hallucinogenic psychedelics for medical use, raising questions about what constitutes a psychedelic experience.
marijuanamoment.net
·

Millions Of Americans With Depression Could Be Eligible For Psilocybin Therapy If ...

A study estimates 24-62% of U.S. depression patients could qualify for psilocybin-assisted therapy if FDA approves, potentially helping millions. Factors influencing eligibility include comorbidities and insurance coverage. The study emphasizes the need for flexible healthcare planning and resource allocation.
mondaq.com
·

Microdosing Psilocybin: Popular Drug Has Implications For The Workplace

The article discusses psilocybin's classification, therapeutic potential, and varying state laws. It highlights the growing interest in psychedelics for treating conditions like depression and PTSD. The article also addresses the legality of microdosing psilocybin, noting its federal illegality but varying state and local enforcement priorities. It provides examples of cities in California that have made psilocybin use a low enforcement priority. The article concludes with recommendations for employers dealing with employees microdosing at work, emphasizing the importance of clear policies and a safe workplace.
ctvnews.ca
·

How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression

Paul Stamets advocates for the respectful use of psilocybin mushrooms, emphasizing their therapeutic potential for conditions like treatment-resistant depression, PTSD, and cluster headaches. Clinical trials have shown psilocybin's effectiveness, leading to FDA recognition as a breakthrough medicine. Psychedelics enhance brain connectivity and neuroplasticity, potentially offering long-term benefits. However, microdosing's efficacy remains scientifically unproven, and psychedelic use carries risks, including potential for psychosis in vulnerable individuals. Researchers aim to develop non-psychedelic alternatives to harness these benefits.
ctvnews.ca
·

How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more

Psilocybin mushrooms, beyond recreational use, show promise in treating depression, PTSD, and other conditions by enhancing brain connectivity and neuroplasticity. Clinical trials highlight their potential as breakthrough medicines, though long-term effects and microdosing benefits remain under study. Therapy is crucial for maximizing benefits, with ongoing research into non-psychedelic alternatives.
jdsupra.com
·

Microdosing Psilocybin: Popular Drug Has Implications for the Workplace

The article discusses psilocybin's therapeutic potential, state laws on its use, and employer responses to employee microdosing. It highlights federal illegality under the Controlled Substances Act, contrasting with state-level decriminalization efforts. Employers are advised to clarify drug use policies, offer employee assistance programs, and ensure safety in safety-sensitive roles.
© Copyright 2025. All Rights Reserved by MedPath